Skip to menu Skip to content Skip to footer
Professor Brian Gabrielli
Professor

Brian Gabrielli

Email: 

Overview

Background

Professor Gabrielli completed his undergraduate education at James Cook University in Townsville and PhD at La Trobe University in Melbourne. After two postdoctoral positions in the USA in the emerging field of cell cycle regulation, he was recruited to establish his own independent research at the Queensland Institute of Medical Research, and then recruited to the Diamantina Institute in 2002, and Mater Research Institute in 2016. He is head of the Smiling for Smiddy Cell Cycle Group.

Research Interests

Mechanisms that regulate cell division, particularly progression into mitosis. These mechanisms are often mutated in cancers and are likely to be major contributors to cancer development. Identifying the genetic mutations that disrupt normal progression and particularly mechanisms, known as checkpoints, provides diagnostic and prognostic opportunities. It also provides potential new targets for chemotherapeutics as drugs targeting defective checkpoints have tumour selective cytotoxic potential.

Research Projects

  • Identifying the molecular basis for defective checkpoints in melanoma.
  • Targeting defective cell cycle responses to ultraviolet radiation, replication stress and TopoII inhibitors in melanoma, and investigating whether the same defects in other cancer types respond to similar targeting.
  • Investigating means of identify very early changes in moles that drive progression to melanoma
  • Targeting Aurora kinases in HPV-driven cancers

Availability

Professor Brian Gabrielli is:
Available for supervision
Media expert

Qualifications

  • Bachelor (Honours) of Science (Advanced), James Cook University
  • Doctor of Philosophy, La Trobe University

Research interests

  • Ultraviolet radiaiton and its contribution to melanoma

  • Targeting defective cell cycle checkpoints in cancers, particularly melanoma

  • Functional genomics; using high throughout screening combined with increased or decreased gene dosage to identify novel regulatory mechanisms and drug targets

  • Mechanism of action studies for novel anti-caner therapeutics

Works

Search Professor Brian Gabrielli’s works on UQ eSpace

163 works between 1984 and 2025

121 - 140 of 163 works

2003

Journal Article

APC mutation and tumour budding in colorectal cancer

Jass, JR, Barker, M, Fraser, L, Walsh, MD, Whitehall, VLJ, Gabrielli, B, Young, J and Leggett, BA (2003). APC mutation and tumour budding in colorectal cancer. Journal of Clinical Pathology, 56 (1), 69-73. doi: 10.1136/jcp.56.1.69

APC mutation and tumour budding in colorectal cancer

2003

Journal Article

Tumor cell-specific cytotoxicity by targeting cell cycle checkpoints

Warrener, R, Beamish, H, Burgess, A, Waterhouse, NJ, Giles, N, Fairlie, DP and Gabrielli, B (2003). Tumor cell-specific cytotoxicity by targeting cell cycle checkpoints. Faseb Journal, 17 (9), 1550-1570. doi: 10.1096/fj.02-1003fje

Tumor cell-specific cytotoxicity by targeting cell cycle checkpoints

2003

Journal Article

Mechanism of mitosis-specific activation of MEK1

Harding, A., Giles, N., Burgess, A., Hancock, J. F. and Gabrielli, B. G. (2003). Mechanism of mitosis-specific activation of MEK1. Journal of Biological Chemistry, 278 (19), 16747-16754. doi: 10.1074/jbc.M301015200

Mechanism of mitosis-specific activation of MEK1

2003

Journal Article

14-3-3 acts as an intramolecular bridge to regulate cdc25B localization and activity

Giles, N., Forrest, A. and Gabrielli, B. (2003). 14-3-3 acts as an intramolecular bridge to regulate cdc25B localization and activity. Journal of Biological Chemistry, 278 (31), 28580-28587. doi: 10.1074/jbc.M304027200

14-3-3 acts as an intramolecular bridge to regulate cdc25B localization and activity

2002

Journal Article

Identifying molecular targets mediating the anticancer activity of histone deacetylase inhibitors: A work in progress

Gabrielli, B. G., Johnstone, R. W. and Saunders, N. A. (2002). Identifying molecular targets mediating the anticancer activity of histone deacetylase inhibitors: A work in progress. Current Cancer Drug Targets, 2 (4), 337-353. doi: 10.2174/1568009023333818

Identifying molecular targets mediating the anticancer activity of histone deacetylase inhibitors: A work in progress

2002

Journal Article

Introduction: Molecular and biomechanical basis of osteoarthritis

Pavey, Sandra, Russell, Terry and Gabrielli, Brian (2002). Introduction: Molecular and biomechanical basis of osteoarthritis. Cellular and Molecular Life Sciences, 59 (1), 3-4. doi: 10.1007/s00018-002-8399-5

Introduction: Molecular and biomechanical basis of osteoarthritis

2002

Journal Article

A histone deacetylase inhibitor, azelaic bishydroxamic acid, shows cytotoxicity on Epstein-Barr virus-transformed B-cell lines - A potential therapy for posttransplant lymphoproliferative disease

Sculley, T. B., Buck, M., Gabrielli, B., Parsons, P. G. and Krauer, K. G. (2002). A histone deacetylase inhibitor, azelaic bishydroxamic acid, shows cytotoxicity on Epstein-Barr virus-transformed B-cell lines - A potential therapy for posttransplant lymphoproliferative disease. Transplantation, 73 (2), 271-279. doi: 10.1097/00007890-200201270-00021

A histone deacetylase inhibitor, azelaic bishydroxamic acid, shows cytotoxicity on Epstein-Barr virus-transformed B-cell lines - A potential therapy for posttransplant lymphoproliferative disease

2002

Journal Article

Tumor-selective toxicity of histone deacetylase inhibitors is due to their targeting cell cycle checkpoint points

Gabrielli, B, Warrener, R, Beamish, H, Burgess, A and Waterhouse, N (2002). Tumor-selective toxicity of histone deacetylase inhibitors is due to their targeting cell cycle checkpoint points. European Journal of Cancer, 38, S95-S95.

Tumor-selective toxicity of histone deacetylase inhibitors is due to their targeting cell cycle checkpoint points

2002

Journal Article

Loss of p16 expression is associated with histological features of melanoma invasion

Pavey, S. J., Cummings, M. C., Whiteman, D. C., Castellano, M., Walsh, M. D., Gabrielli, B. G., Green, A. and Hayward, N. K. (2002). Loss of p16 expression is associated with histological features of melanoma invasion. Melanoma Research, 12 (6), 539-547. doi: 10.1097/01.cmr.0000043154.28051.9f

Loss of p16 expression is associated with histological features of melanoma invasion

2002

Journal Article

alpha-melanocyte stimulating hormone potentiates p16/CDKN2A expression in human skin after ultraviolet irradiation

Pavey, S. and Gabrielli, B. (2002). alpha-melanocyte stimulating hormone potentiates p16/CDKN2A expression in human skin after ultraviolet irradiation. Cancer Research, 62 (3), 875-880.

alpha-melanocyte stimulating hormone potentiates p16/CDKN2A expression in human skin after ultraviolet irradiation

2001

Journal Article

G2 phase cell cycle arrest in human skin following UV irradiation

Pavey, Sandra, Russell, Terry and Gabrielli, Brian (2001). G2 phase cell cycle arrest in human skin following UV irradiation. Oncogene, 20 (43), 6103-6110. doi: 10.1038/sj.onc.1204707

G2 phase cell cycle arrest in human skin following UV irradiation

2001

Journal Article

Cdc25B activity is regulated by 14-3-3

Forrest, A. and Gabrielli, B. (2001). Cdc25B activity is regulated by 14-3-3. Oncogene, 20 (32), 4393-4401. doi: 10.1038/sj.onc.1204574

Cdc25B activity is regulated by 14-3-3

2001

Journal Article

Cdc25-dependent activation of cyclin A/cdk2 is blocked in G2 phase arrested cells independently of ATM/ATR

Goldstone, S., Pavey, S., Forrest, A., Sinnamon, J. and Gabrielli, B. (2001). Cdc25-dependent activation of cyclin A/cdk2 is blocked in G2 phase arrested cells independently of ATM/ATR. Oncogene, 20 (8), 921-932. doi: 10.1038/sj.onc.1204177

Cdc25-dependent activation of cyclin A/cdk2 is blocked in G2 phase arrested cells independently of ATM/ATR

2001

Journal Article

Up-regulation of p21(WAF1)/(CIP1) by histone deacetylase inhibitors reduces their cytotoxicity

Burgess, A. J., Pavey, S., Warrener, R., Hunter, L. J. K., Piva, T. J., Musgrove, E. A., Saunders, N., Parsons, P. G. and Gabrielli, B. G. (2001). Up-regulation of p21(WAF1)/(CIP1) by histone deacetylase inhibitors reduces their cytotoxicity. Molecular Pharmacology, 60 (4), 828-837.

Up-regulation of p21(WAF1)/(CIP1) by histone deacetylase inhibitors reduces their cytotoxicity

2001

Journal Article

Histone hyperacetylation induced by histone deacetylase inhibitors is not sufficient to cause growth inhibition in human dermal fibroblasts

Brinkmann, Hannah, Dahler, Alison L., Popa, Claudia, Serewko, Magdalena M., Parsons, Peter G., Gabrielli, Brian G., Burgess, Andrew J. and Saunders, Nicholas A. (2001). Histone hyperacetylation induced by histone deacetylase inhibitors is not sufficient to cause growth inhibition in human dermal fibroblasts. Journal of Biological Chemistry, 276 (25), 22491-22499. doi: 10.1074/jbc.M100206200

Histone hyperacetylation induced by histone deacetylase inhibitors is not sufficient to cause growth inhibition in human dermal fibroblasts

2000

Journal Article

Histone deacetylase inhibitors trigger a G2 checkpoint in normal cells that is defective in tumor cells

Qiu, Ling, Burgess, Andrew, Fairlie, David P., Leonard, Helen, Parsons, Peter G. and Gabrielli, Brian G. (2000). Histone deacetylase inhibitors trigger a G2 checkpoint in normal cells that is defective in tumor cells. Molecular Biology of the Cell, 11 (6), 2069-2083. doi: 10.1091/mbc.11.6.2069

Histone deacetylase inhibitors trigger a G2 checkpoint in normal cells that is defective in tumor cells

2000

Journal Article

Regulation of CDC25B phosphatases subcellular localization

Davezac, N, Baldin, V, Gabrielli, B, Forrest, A, Theis-Febvre, N, Yashida, M and Ducommun, B (2000). Regulation of CDC25B phosphatases subcellular localization. Oncogene, 19 (18), 2179-2185. doi: 10.1038/sj.onc.1203545

Regulation of CDC25B phosphatases subcellular localization

2000

Journal Article

Centrosomal and cytoplasmic Cdc2/Cyclin B1 activation precedes nuclear mitotic events

De Souza, C. P. C., Ellem, K. A. O. and Gabrielli, B. G. (2000). Centrosomal and cytoplasmic Cdc2/Cyclin B1 activation precedes nuclear mitotic events. Experimental Cell Research, 257 (1), 11-21. doi: 10.1006/excr.2000.4872

Centrosomal and cytoplasmic Cdc2/Cyclin B1 activation precedes nuclear mitotic events

1999

Journal Article

Multiple splicing variants of cdc25B regulate G2/M progression

Forrest, A. R. R., McCormack, A. K., DeSouza, C. P. C., Sinnamon, J. M., Tonks, I. D., Hayward, N. K., Ellem, K. A. O. and Gabrielli, B. G. (1999). Multiple splicing variants of cdc25B regulate G2/M progression. Biochemical and Biophysical Research Communications, 260 (2), 510-515. doi: 10.1006/bbrc.1999.0870

Multiple splicing variants of cdc25B regulate G2/M progression

1999

Journal Article

Functional reassessment of p16 variants using a transfection-based assay

Walker, GJ, Gabrielli, BG, Castellano, M and Hayward, NK (1999). Functional reassessment of p16 variants using a transfection-based assay. International Journal of Cancer, 82 (2), 305-312. doi: 10.1002/(SICI)1097-0215(19990719)82:23.0.CO;2-Z

Functional reassessment of p16 variants using a transfection-based assay

Funding

Current funding

  • 2023 - 2026
    Targeting replication stress to improve immune recognition and reduce immunosuppressive in the tumour microenvironment
    Ovarian Cancer Research Foundation Research Grants
    Open grant

Past funding

  • 2021 - 2024
    Enhancing tumour immune detection by targeting replication stress
    Established Investigator
    Open grant
  • 2018 - 2020
    Towards clinical diagnosis of inflammatory skin rashes using minimally-invasive microsampling techniques
    TRI Spore Grants
    Open grant
  • 2018 - 2019
    Preclinical development of combinations with CHK1 inhibitors in melanoma and lung cancer
    Cancer Council Queensland
    Open grant
  • 2016 - 2019
    Aurora A as a novel therapeutic target for HPV-driven cancers (NHMRC Project Grant administered by Griffith University)
    Griffith University
    Open grant
  • 2016
    Epigenetic remodelling driving acquired permanent drug resistance in melanoma cells
    PA Research Foundation
    Open grant
  • 2015 - 2018
    Defining the role of Microphthalmia-associated Transcription Factor (MITF) in melanoma heterogeneity by real-time cell cycle imaging
    NHMRC Project Grant
    Open grant
  • 2015
    Next-generation cell analysis: Automated high-throughput 3D microscope and multimode microplate reader
    NHMRC Equipment Grant
    Open grant
  • 2015 - 2016
    Novel therapeutic targets for HPV-driven cancers (Cancer Council Queensland grant administered by Griffith University
    Griffith University
    Open grant
  • 2015
    Targeting HPV in oropharyngeal cancers
    PA Research Foundation
    Open grant
  • 2014
    Calibration of single channel and liquid handling robots
    UQ Major Equipment and Infrastructure
    Open grant
  • 2014 - 2016
    Identifying the mechanism of the G2 phase UV checkpoint and repair response commonly defective in melanoma
    NHMRC Project Grant
    Open grant
  • 2014
    Purchase of low O2 incubator and Dissociator
    NHMRC Equipment Grant
    Open grant
  • 2013
    Functional characterization of the regulatory architecture of melanoma-associated loci
    NHMRC Project Grant
    Open grant
  • 2013 - 2015
    Functional characterization of the regulatory architecture of melanoma-associated loci (NHMRC Project Grant administered by Garvan Institute)
    Garvan Institute
    Open grant
  • 2012 - 2015
    Functional assessment of new melanoma genomic mutations
    Worldwide Cancer Research
    Open grant
  • 2012 - 2015
    Determining Predictors of Sensitivity to CHK Inhibitors in Metastatic Melanoma (Cancer Australia grant administered by the University of Melbourne)
    University of Melbourne
    Open grant
  • 2012 - 2013
    Defining a response to UV exposure that is defective in melanoma
    Cancer Council Queensland
    Open grant
  • 2012 - 2015
    Synthetic lethality screen targeting a defective checkpoint in melanoma
    NHMRC Project Grant
    Open grant
  • 2012
    Validation of genes potentially involved in early stage melanoma using immunohistochemistry
    Queensland Pharmacy Research Trust
    Open grant
  • 2011
    Laser Scanner for Biomolecular Imaging
    NHMRC Equipment Grant
    Open grant
  • 2011
    Targeting the G2 phase checkpoint in Glioblastoma to improve the efficacy of current therapy
    Brain Foundation
    Open grant
  • 2010
    Centrosome overduplication contributes to tumorigenesis
    NHMRC Project Grant
    Open grant
  • 2010 - 2015
    NHMRC Research Fellowship: Senior Research Fellowship A
    NHMRC Research Fellowship
    Open grant
  • 2010 - 2012
    Synthetic lethality screen targeting a defective checkpoint in melanoma
    Cancer Council Queensland
    Open grant
  • 2009
    Proteomic studies in cancer, immunology and metabolism research
    UQ Institute Co-Funding
    Open grant
  • 2009 - 2012
    The role of tumour-initiating cells in glioma
    NHMRC Project Grant
    Open grant
  • 2008 - 2009
    Histone deacetylase inhibitors can inhibit tumour growth via induction of an anti-tumour immune response
    Cancer Council Queensland
    Open grant
  • 2008 - 2009
    Is the heterochromatin checkpoint a useful anti-cancer drug target?
    Cancer Council Queensland
    Open grant
  • 2008
    Confocal Microscopy
    UQ Major Equipment and Infrastructure
    Open grant
  • 2007 - 2009
    CDK4 activity in S/G2 phases influences mitotic fidelity
    NHMRC Project Grant
    Open grant
  • 2007 - 2009
    The function of truncated MEK1 in a G2 phase cell cycle delay and in mitosis
    ARC Discovery Projects
    Open grant
  • 2007 - 2009
    Transcriptional complexity of cell cycle regulated genes during cell division and tumorigenesis
    NHMRC Project Grant
    Open grant
  • 2006
    A Facility for High-Throughput, Functional Gene Discovery Using Arrayed Retroviral Expression Cloning
    ARC Linkage Infrastructure, Equipment and Facilities
    Open grant
  • 2006 - 2007
    The molecular basis for the initiation of squamous differentiation
    Queensland Cancer Fund
    Open grant
  • 2005 - 2006
    G2 phase cdk4 activity regulates expression of proteins essential for the fidelity of mitosis: a target for UV-induced p16 expression
    Queensland Cancer Fund
    Open grant
  • 2005 - 2009
    NHMRC SENIOR RESEARCH FELLOWSHIP
    NHMRC Research Fellowship
    Open grant
  • 2004 - 2006
    Function of the unique mitotic form of MEK
    ARC Discovery Projects
    Open grant
  • 2004 - 2006
    Histone Hyperacetylation Affects G2/M Cell Cycle Transition
    NHMRC Project Grant
    Open grant
  • 2004 - 2006
    What Regulates G2 Phase?
    NHMRC Project Grant
    Open grant
  • 2003 - 2004
    Mechanism of UV Induction of the Melanoma Susceptibility Gene Product P16CDKN2A in Skin
    Queensland Cancer Fund
    Open grant
  • 2003
    Zeiss Cell Observer Video Microscopy System
    NHMRC Equipment Grant
    Open grant
  • 2002 - 2003
    Mitotic regulation of the Ras/Raf/MEK/ERK pathway
    Queensland Cancer Fund
    Open grant
  • 2001 - 2002
    NHMRC Equipment Grant 2000
    NHMRC Equipment Grant
    Open grant
  • 2000 - 2001
    Does increased p21 WAF1 expression effect the mechanism of histone deacetylase inhibitor-induced cell death?
    UQ New Staff Research Start-Up Fund
    Open grant

Supervision

Availability

Professor Brian Gabrielli is:
Available for supervision

Before you email them, read our advice on how to contact a supervisor.

Available projects

  • Identifying the molecular basis for defective checkpoints in melanoma

  • Targeting defective cell cycle responses to ultraviolet radiation and TopoII inhibitors in melanoma

  • Defining the molecular changes in moles underpinning morphological changes detectable by non-invasive imaging techniques to improve their diagnostic and prognostic ability for early stage melanoma

Supervision history

Current supervision

  • Doctor Philosophy

    AURKi enhances replication stress targeted by CHK1i in p53 and RB defective cells

    Principal Advisor

  • Doctor Philosophy

    Targeting RB and p53 Mutant Cancers with Aurora Kinase B Inhibition

    Principal Advisor

  • Doctor Philosophy

    Enhancing immune responses to cancer

    Principal Advisor

    Other advisors: Dr Jazmina Gonzalez Cruz

  • Doctor Philosophy

    Assessment of cell cycle phase-dependent immunogenicity of melanoma treated with the proteasome inhibitor bortezomib

    Associate Advisor

    Other advisors: Professor Nikolas Haass

  • Doctor Philosophy

    Modulating phenotypic melanoma heterogeneity and lymphocyte infiltration to improve both targeted and immune therapy

    Associate Advisor

    Other advisors: Dr Janin Chandra, Professor Nikolas Haass

  • Doctor Philosophy

    Chemoprevention of Melanoma using natural products and TRAIL- based therapeutics.

    Associate Advisor

    Other advisors: Professor Peter Soyer, Associate Professor Helmut Schaider, Dr Zyta M Ziora, Dr Jazmina Gonzalez Cruz

Completed supervision

Media

Enquiries

Contact Professor Brian Gabrielli directly for media enquiries about:

  • Anti-cancer drugs
  • Cancer - drugs to prevent
  • Cancer - skin
  • Cancer - treatment
  • Cell cycle
  • Drugs - anti-cancer
  • Melanoma
  • Mitosis
  • Radiation - ultraviolet
  • Skin cancer
  • Sun cancer
  • Ultraviolet radiation
  • UV rays

Need help?

For help with finding experts, story ideas and media enquiries, contact our Media team:

communications@uq.edu.au